Eisai Inc Drug Patent Portfolio

Eisai Inc's Family Patents

Drugs Generating Over $1 Billion in Annual Revenue

Explore the top-performing drugs that dominate the pharmaceutical industry

View List

NCE-1 Patent Expiry in the Next 1 Year

Identify opportunities as new chemical entity (NCE-1) patents approach expiry

View List

Recently Granted Patents in EP

Find the opportunity to file Oppositions

View List

Lessons from Cancer Treatment Applied to Alzheimer's: A Multi-Target Drug Approach - OC Academy

12 Dec, 2025

Alzheimer's medication research draws inspiration from cancer treatment strategies that focus on multiple targets - The Japan Times

12 Dec, 2025

Eisai and Merck successfully fend off generic rivals for their popular cancer medication, Lenvima.

29 May, 2025

Eisai and Merck Successfully Maintain Lenvima Patent Against Shilpa's Challenge - Bloomberg Law

28 May, 2025